Expands pipeline of T cell engaging bispecific antibodies through acquisitions of CT-95, a Mesothelin x CD3 bispecific antibody, and CT-202, a Nectin-4 x CD3 bispecific antibody Strengthens board with appointments of Dr. Karen Smith and Dr. Luke Walker Cash and cash equivalents of $84.8 million as of September 30, 2024 PHILADELPHIA, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engagers for solid tumors, ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________ FORM 10-Q ___________________________________ (Mark one) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ______________. Commission file number: 001-40654 CONTEXT THERAPEUTICS ...

PHILADELPHIA, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engagers for solid tumors, today announced that the Company will participate in the following investor conferences in November: Guggenheim Global Healthcare Conference: Fireside chat on Monday, November 11, 2024, at 3:00 p.m. ET in Boston, MA. UBS Global Healthcare Conference: Fireside chat on Wednesday, November 13, 2024, at 11:45 a.m. PT in Rancho ...

PHILADELPHIA, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced the appointments of Karen Smith, MD, PhD, MBA, LLM and Luke Walker, MD, to its Board of Directors. "Karen and Luke's vast experience and proven leadership in the biopharmaceutical industry are tremendous assets for Context at this pivotal stage of our growth," said Martin Lehr, CEO of Context Therapeutics. "K ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Context Therapeutics Inc. (CNTX) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out. Context Therapeutics Inc. is one of 1017 companies in the Medical group. The Medical group currently sits at #5 within the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the ...

Announced acquisition of CT-95, a mesothelin x CD3 bispecific antibody Claudio Dansky Ullmann, M.D. named Chief Medical Officer Cash and cash equivalents of $101.5 million as of June 30, 2024 PHILADELPHIA, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced its financial results for the second quarter ended June 30, 2024, and reported on recent business highlights. "Context ...

生物治疗药物研发 - 公司正在开发两款T细胞双特异性生物治疗药物CTIM-76和CT-95[102,103,106] - CTIM-76是一种针对CLDN6的双特异性抗体,已完成IND申请并获FDA批准,计划于2024年第三季度开始I期临床试验[103] - CT-95是一种针对MSLN的双特异性抗体,公司已完成收购并计划于2025年第一季度开始I期临床试验[104,106] 融资与运营 - 公司于2024年5月完成1亿美元的私募融资,用于CTIM-76和CT-95的研发以及日常运营[107,108,109] - 公司预计现有现金可支持CTIM-76I期试验和CT-95剂量递增试验,以及公司运营到2028年[118,119] - 公司预计未来将通过股权融资、债务融资等方式筹集运营所需资金[149][150] - 经营活动现金流出7.716百万美元,主要用于CTIM-76项目的研发[153] - 筹资活动现金流入9.48亿美元,主要来自私募配售[155] 财务表现 - 研发费用同比下降60%,主要是ONA-XR项目停止开发和CTIM-76项目研发费用减少[131][132][133] - 一般及行政费用同比下降7%,主要是薪酬和股份支付成本以及保险费用减少[134] - 利息收入同比增加186%,主要是由于私募配售后现金及等价物余额增加[135] - 其他费用同比下降50%,主要是外汇损失减少[136] - 现金及等价物余额为1.015亿美元,预计可支持CTIM-76和CT-95 Phase 1试验以及公司运营到2028年[145][146] 公司地位与披露 - 公司已于2024年2月修订了CTIM-76相关的许可协议,调整了里程碑付款和特许权使用费[111,112,113] - 公司决定停止ONA-XR的开发,将重点集中在CTIM-76和CT-95的开发[114] - 公司已选择利用JOBS法案的豁免条款,可以延迟采用新的或修订的会计准则,财务报表可能与其他公司不具有可比性[159] - 公司无需提供内部控制审计报告,无需进行强制性审计事务所轮换,可以减少高管薪酬披露[160] - 公司将一直保持"新兴成长公司"地位,直到满足一定条件[160] - 公司同时也是"较小报告公司",可以享受较小报告公司的一些披露豁免[161] - 作为较小报告公司,公司可以只披露最近两个财年的经审计财务报表[161] - 公司作为较小报告公司无需提供市场风险的量化和定性披露[162]

Company announces appointments of Dr. Claudio Dansky Ullmann as CMO and Ms. Karen Andreas as VP, Clinical Operations Appointments support the development of the Company's two clinical-stage T cell engaging assets to treat solid tumors PHILADELPHIA, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced the appointment of Claudio Dansky Ullmann, M.D. as Chief Medical Officer ("C ...

Company announces appointments of Dr. Claudio Dansky Ullmann as CMO and Ms. Karen Andreas as VP, Clinical Operations Appointments support the development of the Company's two clinical-stage T cell engaging assets to treat solid tumors PHILADELPHIA, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced the appointment of Claudio Dansky Ullmann, M.D. as Chief Medical Officer ("C ...

CT-95 is a potentially first-in-class mesothelin x CD3 bispecific antibody Acquisition expands Context pipeline with second clinical-stage T cell engager for solid tumors PHILADELPHIA, July 10, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced that it has entered into an asset purchase agreement under which the Company has acquired CT-95, formerly owned by Link Immunotherapeutics, ...